Brennan Mulcahy, Chair, is the former CEO of Energy Saving Income Fund, Toronto, ON, a publicly-traded company with sales of over 2 billion dollars last year. He has been involved in the deregulation of natural gas for 18 years.
John Bell, PhD, CSO of Jennerex (see management section)
Paul B. Cleveland brings over 20 years of experience in strategic corporate transactions and investment banking to the Jennerex board. As executive vice president of corporate development and chief financial officer for Affymax, he manages all business development, strategic planning, financial and legal activities. Prior to Affymax, he served as managing director of the investment banks Integrated Finance, Ltd. and J.P. Morgan Chase and Co. (formerly Hambrecht & Quist), leading healthcare and technology mergers and acquisitions for the firms. Prior to his tenure in investment banking, he was a partner at Cooley Godward LLP. Mr. Cleveland serves as a member of the board of directors of Sangamo BioSciences, Inc. He holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.
Hoyoung Huh, M.D., Ph.D. has been involved in the formation and management of multiple biopharm companies. Most recently Dr. Huh was CEO of BiPar Sciences where he led the merger of BiPar with Sanofi-aventis (NYSE: SNY), and he now serves as Chairman of BiPar. He currently serves on the board of several other major biopharm companies, including Epizyme, Inc., Facet Biotech (NASDAQ: FACT), Interplast, and BayBio. Dr. Huh was previously a member of the Board and COO at Nektar Therapeutics (NASDAQ: NKTR), a drug development company focused on oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led partnerships with major pharmaceutical companies, including Bayer, Roche, Baxter, Novartis, and Pfizer. As an industry thought leader, Dr. Huh speaks frequently on innovation, entrepreneurship, and biotechnology strategies. Dr. Huh was formerly a Partner at McKinsey and Co., as a leader in the biotechnology sector. Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor's degree in biochemistry from Dartmouth College.
David Kirn, MD, CEO and Co-Founder of Jennerex (see management section)
Martin J. Murphy, Jr., PhD, DMedSc is the Founding Chairman and CEO of AlphaMed Consulting, Inc. that provides strategic support to cancer centers, advocacy groups as well as the global pharmaceutical and biotechnology industry. He is Founding Executive Editor of the international, peer-reviewed journal, ěThe Oncologistî, which is read by more than 21,000 physicians. He founded and was the CEO of the Hipple Cancer Research Center where he was principal investigator of $12M of cancer research grant. He is also founding convener of the CEO Roundtable on Cancer, first-chaired by Robert A. Ingram at the request of former President George H.W. Bush.
Ken Newport, C.A., M.Acc. co-founded CroMedica International Inc., a contract research organization, in 1995. In 2002, CroMedica was sold to PRA International, one of the world's largest contract research organizations. From 2002 to 2005 Mr. Newport was Senior Vice President of PRA's International Business Development, following which he retired. Mr. Newport is a director of Zelos Therapeutics.
Ron Vered, P.Eng., is CEO of Arnon Corporation and past President of Ron Engineering and Construction (Eastern) Ltd., privately-owned real estate and construction companies based in Ottawa with international experience. Through the Vered Foundation, the Vered family has been active in and supportive of numerous causes including the United Jewish Appeal, the University of Ottawa Heart Institute, the University of Ottawa and the Ottawa Hospital. Mr. Vered is a Member of the Board of Trustees of S.C.O. Health Service and University of Ottawa Heart Institute.
Robert Donaldson, LL.B., Board Secretary, is Chief Legal Counsel for Energy Saving Income Fund.
Glen Sato, Corporate Secretary, is a partner in the Life Sciences practice group at Cooley Godward in Palo Alto. Prior to rejoining Cooley in 2006, Mr. Sato most recently served as PDL's senior vice president and chief financial officer. He joined PDL from Exelixis, Inc., where he served as senior vice president, chief financial officer and general counsel from November 1999 to May 2003. Prior to his time at Exelixis, he served in various legal and strategic planning positions at PDL, including vice president, legal and general counsel. In addition, Mr. Sato worked for Steve Jobs at NeXT Computer, Inc. where he served under Doug Ebersole as associate general counsel. He was an attorney in Cooley Godward's business department in Palo Alto for two years. Mr. Sato received his JD and MBA from UCLA, where he was an associate editor of the Law Review.